Prevention of Type 2 Diabetes in Subjects With Prediabetes and Metabolic Syndrome Treated With Phentermine and Topiramate Extended Release
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To evaluate over 108 weeks the effect of phentermine and topiramate extended release (PHEN/TPM ER) treatment on progression to type 2 diabetes and/or cardiometabolic disease in subjects with prediabetes and/or metabolic syndrome (MetS) at baseline. RESEARCH DESIGN AND METHODS: Subanalysis of a phase 3, randomized, placebo-controlled, double-blind study of overweight/obese subjects (BMI ≥27 to ≤45 kg/m2) with two or more comorbidities. Subjects were randomized to placebo, PHEN 7.5 mg/TPM ER 46 mg (7.5/46), or PHEN 15 mg/TPM ER 92 mg (15/92) plus lifestyle modifications for 108 weeks. Percent weight loss in the intent-to-treat population using multiple imputation (ITT-MI), annualized incidence rate of progression to type 2 diabetes, and changes in glycemia, lipid parameters, blood pressure, and waist circumference were evaluated. RESULTS: At baseline, 475 subjects met the criteria for prediabetes and/or MetS. After 108 weeks, subjects with prediabetes and/or MetS in the placebo, 7.5/46, and 15/92 groups experienced mean percent weight loss of 2.5, 10.9, and 12.1%, respectively (ITT-MI; P < 0.0001 vs. placebo), associated with reductions of 70.5 and 78.7% in the annualized incidence rate of type 2 diabetes for those receiving 7.5/46 and 15/92, respectively (ITT, P < 0.05), versus placebo. The ability of PHEN/TPM ER to prevent diabetes was related to degree of weight lost and was accompanied by significant improvements in cardiometabolic parameters. PHEN/TPM ER was well tolerated by this subgroup over 2 years. CONCLUSIONS: PHEN/TPM ER plus lifestyle modification produced significant weight loss and markedly reduced progression to type 2 diabetes in overweight/obese patients with prediabetes and/or MetS, accompanied by improvements in multiple cardiometabolic disease risk factors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In a post hoc CONQUER analysis, phentermine/topiramate ER reduced T2D progression by 48–78% over 56 weeks, depending on dose and baseline glycemia, driven by up to 10.9% weight loss and improved insulin sensitivity [26].”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [26]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This agent induces significant weight loss (10–12%) [26] which may alleviate OA symptoms. However, OA-specific data are lacking, and use remains extrapolative.”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [26]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The translation of the structured lifestyle intervention used in the Diabetes Prevention Program to community-based programs, commercial programs, and programs using remote technologies have achieved less weight loss than observed in the Diabetes Prevention Program trial itself.861–869”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [865]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“A meta-analysis of 44 Diabetes Prevention Program translation studies reported an average 9.3-month weight loss of 3.77 kg from participants’ baseline weight and a decrease in fasting glucose of 2.4 mg/dL.865”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [865]
Experimental — accuracy not yet measuredIn the citing paper
“Phentermine/topiramate ER reduced incident T2DM in patients with prediabetes or metabolic syndrome by 79%.”
From The Vasculature in Prediabetes (2018) · cites this paper as [193]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Multiple Imputation for Nonresponse in Surveys
Rubin, D. B. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316696 · Cited by 20,701
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · cited 7×
“The DPP study, wherein patients achieved ;6% mean weight loss at 2 years and ;4% weight loss at 4 years in the lifestyle intervention arm, reported a progressive 16% reduction in type 2 diabetes risk with every kilogram of weight loss but without an indication that there was a threshold of weight loss for maximal type…”
BackgroundMethodInfluentialAlberti, K. G. M. M., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., Fruchart, J.-C., James, W. P. T., Loria, C. M., & Smith, S. C. (2009) · Circulation · doi:10.1161/circulationaha.109.192644 · Cited by 14,860
Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Smith, S. C., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.169404 · Cited by 11,961
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
(1998) · PsycEXTRA Dataset · doi:10.1037/e565682010-001 · Cited by 9,472
Eckel, R. H., Alberti, K., Grundy, S. M., & Zimmet, P. Z. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61794-3 · Cited by 6,295
Analysis of Incomplete Multivariate Data
Booth, D. E. (2000) · Technometrics · doi:10.1080/00401706.2000.10486013 · Cited by 5,627
Eckel, R. H., Grundy, S. M., & Zimmet, P. Z. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66378-7 · Cited by 5,550
Pan, X.-R., Li, G.-W., Hu, Y.-H., Wang, J.-X., Yang, W.-Y., An, Z.-X., Hu, Z.-X., Juan-Lin, Xiao, J.-Z., Cao, H.-B., et al. (1997) · Diabetes Care · doi:10.2337/diacare.20.4.537 · Cited by 4,320
Diabetes Prevention Program Research Group (2009) · The Lancet · doi:10.1016/s0140-6736(09)61457-4 · Cited by 3,020
Standards of Medical Care in Diabetes—2012
(2012) · Diabetes Care · doi:10.2337/dc12-s011 · Cited by 2,240
Wiley Series in Probability and Mathematics Statistics
(1981) · Wiley Series in Probability and Statistics · doi:10.1002/0471725250.scard · Cited by 2,220
The Finnish Diabetes Prevention Study (DPS)
Lindström, J., Louheranta, A., Mannelin, M., Rastas, M., Salminen, V., Eriksson, J., Uusitupa, M., Tuomilehto, J., & for the Finnish Diabetes Prevention Study Group (2003) · Diabetes Care · doi:10.2337/diacare.26.12.3230 · Cited by 1,848
Lindström, J., Ilanne-Parikka, P., Peltonen, M., Aunola, S., Eriksson, J. G., Hemiö, K., Hämäläinen, H., Härkönen, P., Keinänen-Kiukaanniemi, S., Laakso, M., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69701-8 · Cited by 1,799
Li, G., Zhang, P., Wang, J., Gregg, E. W., Yang, W., Gong, Q., Li, H., Li, H., Jiang, Y., An, Y., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60766-7 · Cited by 1,600
Impaired Fasting Glucose and Impaired Glucose Tolerance
Nathan, D. M., Davidson, M. B., DeFronzo, R. A., Heine, R. J., Henry, R. R., Pratley, R., & Zinman, B. (2007) · Diabetes Care · doi:10.2337/dc07-9920 · Cited by 1,396
Self-citationEffect of weight loss with lifestyle intervention on risk of diabetes
Hamman, R. F., Wing, R. R., Edelstein, S. L., Lachin, J. M., Bray, G. A., Delahanty, L., Hoskin, M., Kriska, A. M., Mayer-Davis, E. J., Pi-Sunyer, X., et al. (2006) · Diabetes Care · doi:10.2337/dc06-0560 · Cited by 1,344
Grundy, S. M. (2011) · Atlas of Atherosclerosis and Metabolic Syndrome · doi:10.1007/978-1-4419-5839-6_1 · Cited by 1,223
Gadde, K. M., Allison, D. B., Ryan, D. H., Peterson, C. A., Troupin, B., Schwiers, M. L., & Day, W. W. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60205-5 · Cited by 1,064 · cited 6×
“gov, NCT00553787) (25) and was followed by SEQUEL, a 52-week blinded extension study (NCT00796367) (26).”
BackgroundMethodInfluentialSelf-citationThe Metabolic Syndrome as Predictor of Type 2 Diabetes
Lorenzo, C., Okoloise, M., Williams, K., Stern, M. P., & Haffner, S. M. (2003) · Diabetes Care · doi:10.2337/diacare.26.11.3153 · Cited by 803
Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects
Carlsson, L. M. S., Peltonen, M., Ahlin, S., Anveden, Å., Bouchard, C., Carlsson, B., Jacobson, P., Lönroth, H., Maglio, C., Näslund, I., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112082 · Cited by 794
Garvey, W. T., Ryan, D. H., Look, M., Gadde, K. M., Allison, D. B., Peterson, C. A., Schwiers, M., Day, W. W., & Bowden, C. H. (2012) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.111.024927 · Cited by 716 · cited 11×
“In general, PHEN/TPM ER was well tolerated, with no meaningful differences in safety in the prediabetes and/or MetS cohort during 108 weeks when compared with the overall SEQUEL population, and no differences between years 1 and 2 (26).”
InfluentialSelf-citationAllison, D. B., Gadde, K. M., Garvey, W. T., Peterson, C. A., Schwiers, M. L., Najarian, T., Tam, P. Y., Troupin, B., & Day, W. W. (2012) · Obesity · doi:10.1038/oby.2011.330 · Cited by 711
Self-citation[The Da Qing IGT and Diabetes study].
Ayame, H. (2005) · PubMed · Cited by 658
Physical Activity in the Prevention of Type 2 Diabetes
Laaksonen, D. E., Lindström, J., Lakka, T. A., Eriksson, J. G., Niskanen, L., Wikström, K., Aunola, S., Keinänen-Kiukaanniemi, S., Laakso, M., Valle, T. T., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.1.158 · Cited by 614
Colquitt, J. L., Picot, J., Loveman, E., & Clegg, A. J. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003641.pub3 · Cited by 605
Insulin Resistance: the Link Between Obesity and Cardiovascular Disease
Reaven, G. M. (2011) · Medical Clinics of North America · doi:10.1016/j.mcna.2011.06.002 · Cited by 395 · cited 1×
“Since insulin resistance, dyslipidemia, inflammation, and dysregulated secretion of adipocytokines are all hallmarks of cardiometabolic disease, these findings are indicative of the potential reversal of this pathophysiologic process (37,38).”
BackgroundLong-term non-pharmacological weight loss interventions for adults with type 2 diabetes mellitus
Norris, S. L., Zhang, X., Avenell, A., Gregg, E., Brown, T., Schmid, C. H., & Lau, J. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004095.pub2 · Cited by 351
Lara-Castro, C., Fu, Y., Chung, B. H., & Garvey, W. T. (2007) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32814a645f · Cited by 315 · cited 1×
“Since insulin resistance, dyslipidemia, inflammation, and dysregulated secretion of adipocytokines are all hallmarks of cardiometabolic disease, these findings are indicative of the potential reversal of this pathophysiologic process (37,38).”
BackgroundSelf-citationThe Metabolic Syndrome and Inflammation
Sutherland, J. P., McKinley, B., & Eckel, R. H. (2004) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2004.2.82 · Cited by 243 · cited 1×
“Finally, at week 56, high-sensitivity C-reactive protein (hs-CRP) and fibrinogen, both of which are inflammatory markers associated with MetS, were measured, as was adiponectin, which is decreased in subjects with obesity and cardiometabolic disease (28).”
BackgroundKofman, M. D., Lent, M. R., & Swencionis, C. (2010) · Obesity · doi:10.1038/oby.2010.27 · Cited by 220
Elobeid, M. A., Padilla, M. A., McVie, T., Thomas, O., Brock, D. W., Musser, B., Lu, K., Coffey, C. S., Desmond, R. A., St-Onge, M.-P., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006624 · Cited by 158 · cited 1×
“To accommodate missing data, multiple imputation (MI) was applied to all end points where missing data were apparent using, specifically, a 2-step imputation process with m = 5 imputations per step (29).”
MethodLong-term non-pharmacological weight loss interventions for adults with prediabetes
Norris, S. L., Zhang, X., Avenell, A., Gregg, E., Schmid, C. H., & Lau, J. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005270 · Cited by 60 · cited 1×
“These findings have particular relevance to real-world treatment decisions, since maintaining clinically meaningful weight loss through lifestyle changes alone is challenging (16,17).”
Current treatment options for the metabolic syndrome
DEEDWANIA, P. C., & Волкова, Н. И. (2005) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-005-0007-1 · Cited by 59 · cited 1×
“proven to be effective in preventing progression from prediabetes (3,10–13) and MetS (10,14) to type 2 diabetes.”
BackgroundThe Pharmacological Treatment and Management of Obesity
Hussain, S. S., & Bloom, S. R. (2011) · Postgraduate Medicine · doi:10.3810/pgm.2011.01.2243 · Cited by 54
Risk factor assessment for new onset diabetes: literature review
Bakris, G. L., Stockert, J., Molitch, M. E., Zhou, Q., Champion, A., Bacher, P. H., Sowers, J. R., & on behalf of the STAR Investigators (2008) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00925.x · Cited by 39
Update on the Prevention of Type 2 Diabetes
Karam, J. G., & McFarlane, S. I. (2010) · Current Diabetes Reports · doi:10.1007/s11892-010-0163-x · Cited by 27 · cited 1×
“also ameliorates the cardiometabolic disease process, as shown by an increase in insulin sensitivity and a reduction in cardiovascular disease risk factors (12,13,15).”
Background
Research works printed but not linked: 1
- Brownell, 2000, The LEARN Program for Weight Management
Cited by
DeFronzo, R. A., Ferrannini, E., Groop, L., Henry, R. R., Herman, W. H., Holst, J. J., Hu, F. B., Kahn, C. R., Raz, I., Shulman, G. I., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.19 · Cited by 2,611
Self-citationGarvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Self-citationNutrition Therapy for Adults With Diabetes or Prediabetes: A Consensus Report
Evert, A. B., Dennison, M., Gardner, C. D., Garvey, W. T., Lau, K. H. K., MacLeod, J., Mitri, J., Pereira, R. F., Rawlings, K., Robinson, S., et al. (2019) · Diabetes Care · doi:10.2337/dci19-0014 · Cited by 1,496
Self-citationThe Role of Inflammation in Diabetes: Current Concepts and Future Perspectives
Tsalamandris, S., Antonopoulos, A. S., Oikonomou, E., Papamikroulis, G.-A., Vogiatzi, G., Papaioannou, S., Deftereos, S., & Tousoulis, D. (2019) · European Cardiology Review · doi:10.15420/ecr.2018.33.1 · Cited by 1,381
Cusi, K., Isaacs, S., Barb, D., Basu, R., Caprio, S., Garvey, W. T., Kashyap, S., Mechanick, J. I., Mouzaki, M., Nadolsky, K., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.03.010 · Cited by 1,021
Self-citation
Metadata
- Authors
- Garvey, W. T., Ryan, D. H., Henry, R., Bohannon, N. J. V., Toplak, H., Schwiers, M., Troupin, B., & Day, W. W.
- Affiliations
- University of Alabama at Birmingham (US)
- Pennington Biomedical Research Center (US)
- University of California San Diego (US)
- Monteagle Medical Center, San Francisco, CA
- Medical University of Graz (AT)
- Medpace (United States) (US)
- Vivus (United States) (US)
- Corresponding author
- Garvey, W. Timothy
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2014-03-08
- Volume
- 37
- Issue
- 4
- Pages
- 912-921
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC4392900
- OpenAlex
- W2149822561
- Cited by
- 215
- References
- 42
- Citations by year
- 2026: 11 · 2025: 11 · 2024: 17 · 2023: 20 · 2022: 14 · 2021: 16 · 2020: 19 · 2019: 17 · 2018: 22 · 2017: 16 · 2016: 14 · 2015: 20 · 2014: 15
- FWCI
- 12.75
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Veterans Affairs (I01CX000432)
- National Institutes of Health (5p60dk079626-05)
- National Institute of Diabetes and Digestive and Kidney Diseases (P60-DK-079626, P30DK079626)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- type 2 diabetes prevention, prediabetes, metabolic syndrome, obesity, weight loss, cardiometabolic risk factors, lifestyle modification, glycemic control, lipid profile, blood pressure, waist circumference
- MeSH terms
- Topiramate, Delayed-Action Preparations, Diabetes Mellitus, Type 2, Female, Fructose, Humans, Life Style, Male, Middle Aged, Phentermine, Placebos, Prediabetic State, Anti-Obesity Agents, Metabolic Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.